Astellas Pharma Europe Ltd. -- AGAR Award 2013
20. 11. 2012. Astellas Pharma Europe are pleased to announce the launch of the Astellas Grant in Anti-Infectives Research (AGAR) award.
The award programme is set up to provide support to explore basic research that may one day lead to important innovations in the field of anti-infectives. The purpose of the programme is to support research that advances medical and scientific knowledge and that is likely to make an impact on patient care. The focus for 2013 will be on Clostridium difficile infection (CDI).
The award is open to healthcare professionals, working in a healthcare setting from Europe, the Middle East and North Africa who have an innovative idea for research that may ultimately improve patient care. Funding for each award will be up to €50,000 with a maximum award fund for 2013 of €100,000.
Dr Ayad Abdulahad, Vice President of Medical Affairs and Health Economics for Astellas Pharma Europe Ltd., said “Astellas are committed to support anti-infectives research, and it is hoped that this award will make a real difference in improving patient care.”
The deadline for applications is Thursday, 31 January 2013. To apply online and for the full terms and conditions please visit www.agar-research.eu
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd., located in the UK, is the European headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation’s focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 4,300 staff across these regions. For more information about Astellas Pharma Europe, please visit www.astellas.eu.
For further information please contact:
Corporate Communications Director
Tel: +44 (0)203 379 8035 / +44 7826 912 339